United Kingdom

People: Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

19 Jul 2019
Change (% chg)

$-0.32 (-0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Tallett, Elizabeth 

Ms. Elizabeth E. Tallett has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2011. She joined the Company's Supervisory Board as well as the Audit Committee and Compensation Committee in 2011. She is Chairwoman of the Compensation Committee, Member of the Audit Committee and Member of the Selection and Appointment Committee. She was a Principal of Hunter Partners, LLC, a management company for early to mid-stage pharmaceutical, biotechnology and medical device companies, from 2002 until February 2015. Ms. Tallett will continue to consult with early stage health care companies. Her senior management experience includes President and CEO of Transcell Technologies Inc., President of Centocor Pharmaceuticals, member of the Parke-Davis Executive Committee, and Director of Worldwide Strategic Planning for Warner-Lambert Company. Ms. Tallett graduated from The University of Nottingham, England with dual Bachelor's degrees with honors in mathematics and economics. She is a member of the board of directors of Principal Financial Group, Inc. (where she is currently the Lead Director), Anthem, Inc. and Meredith Corp. She is a former director of Varian, Inc., Immunicon, Inc., Varian Semiconductor Equipment Associates, Inc., Coventry Health Care, Inc. and IntegraMed America, Inc. Ms. Tallett was a founding board member of the Biotechnology Council of New Jersey and is a Trustee of Solebury School in Pennsylvania.

Basic Compensation

Total Annual Compensation, USD 96,500
Restricted Stock Award, USD 9,866
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 106,366

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --